By this way, we confirmed that ANTXR1 expression and the proportion of ANTRX1+ CAF-S1 were reduced following chemotherapy in an independent cohort of HGSOC patients (Turku cohort), as well as in BC (Fig. 3F, G), strengthening the validity of our observations both in ovarian and breast cancer. Here, ANTXR1 is linked to breast cancer.